The Medical Advisor

Quick Answer:  The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress is driven by combining precision diagnostics, immunotherapy, and targeted agents — not a single cure. Despite  trillions spent on cancer research  ( The Lancet Oncology ), cancer still  kills around 10 million people a year  ( WHO )...

Introduction In an era where conventional cancer treatments often come with significant side effects and variable success rates, alternative therapies are gaining attention for their potential accessibility and lower toxicity. This exploration delves into the emerging use of topical ivermectin—a well-established antiparasitic medication—for treating skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. Drawing from a compilation of anecdotal success stories, case reports, and preliminary scientific insights, we examine how this affordable, over-the-counter option might disrupt traditional dermatological approaches. While not a substitute for professional medical advice, these narratives highlight patient-driven innovations that challenge the status quo, prompting a closer look at ivermectin's multifaceted mechanisms and real-world applications. Case Presentations Case 16 - 2026: 66 year old Texas nurse with Basal Cell Carcinoma at the nose/cheek jun...